Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00406380
Status:
WITHDRAWN
Last Update Posted:
2024-05-30
First Post:
2006-11-30
Brief Title:
Effect of Avastin in Juxtafoveal Telangiectasias
Sponsor:
Asociación para Evitar la Ceguera en México
Organization:
Asociación para Evitar la Ceguera en México
Study Overview
Official Title:
Does Avastin Change Evolution in Juxtafoveal Telangiectasias
Status:
WITHDRAWN
Status Verified Date:
2024-05
Last Known Status:
Recruiting
Delayed Posting:
No
If Stopped, Why?:
Undefined
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias
Detailed Description:
After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram FAfindings we treated patients with Intravitreal Injection of Bevacizumab 25mg01ml We performed a complete ophthalmological evaluation and at baseline and follow-up 1 and 3 months we evaluate ETDRS Best Corrected visual acuity BCVA fluorescein angiogram FA and Optical Coherence Tomography OCTfindings We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None